Malin Assets


Our Assets give investors access to life sciences businesses with unique exposure across diverse modalities, therapeutic areas and geographies.

Poseida is a clinical-stage biopharmaceutical company building out a wholly-owned pipeline of Chimeric antigen receptor T cell (CAR-T) product candidates, initially focused on the treatment of haematologoical malignancies, like multiple myeloma, and solid tumours, like prostate cancer.

> read more
> go to website

Immunocore is a leading clinical-stage T Cell Receptor (TCR) biotechnology company delivering first-in-class biological therapies, focused on oncology, infectious and autoimmune diseases.

> read more
> go to website

Viamet represents a financial interest for Malin in VIVJOA™, an FDA-approved medication for the treatment of recurrent vulvovaginal candidiasis (RVVC), an unmet need in women’s health, and in a Phase 3 compound for the treatment of onychomycosis, fungal nail infection.

> read more
> go to website

Xenex is a commercial-stage medical device company focused on reducing healthcare-associated infections with its unique non-mercury, full-spectrum disinfection LightStrikeTM Germ-ZappingTM robots. Xenex aims to become the new standard of care for disinfection in healthcare facilities worldwide, eliminating harmful bacteria, viruses and fungi which can cause healthcare associated infections in patients and staff.

> go to website

CG Oncology is an oncolytic immunotherapy company that is intensely focused on developing bladder saving therapeutics for patients with bladder cancer. At CG Oncology we see a world where urologic cancer patients can benefit from our innovative therapies to live and work with dignity and an enhanced quality of life.

> go to website

Wren is a spin-off company from the University of Cambridge (UK) and Lund University (Sweden) focused on drug discovery and development for protein misfolding diseases including Alzheimer's and Parkinson's. Wren’s proprietary approach is based on more than a decade of research focused on the chemical kinetics of the protein misfolding process. Wren is developing a broad pipeline of small molecule and antibody therapeutics, as well as diagnostics, spanning neurology, ophthalmology and metabolic diseases.

> go to website

KNOW Bio is a privately held life science company utilising its extensive catalogue of intellectual property in the fields of nitric oxide and precision light therapy to develop unique treatments to revolutionise the standard of care for many indications.

> go to website

Artizan is an early-stage biotechnology company focused on developing a platform to eliminate disease-causing bacteria in the gut microbiota. Artizan's initial focus is on inflammatory bowel disease, specifically Crohn's Disease and Ulcerative Colitis.

> go to website